Skip to content

Study · Randomized controlled trial · n = 127 · 2007

4 results

Desmopressin in the treatment of nocturia: a double-blind, placebo-controlled study.

van Kerrebroeck P, Rezapour M, Cortesse A, Thüroff J, Riis A, Nørgaard JP

European urology16 Jan 2007Cited by 97 (Europe PMC)

PMID17280773 (opens in a new tab)DOI10.1016/j.eururo.2007.01.027 (opens in a new tab)PepBankPUB-17280773
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with nocturia, 20 desmopressin recipients (33%) versus seven placebo recipients (11%) achieved at least 50% fewer nocturnal voids (p=0.0014).

    In plain wordsIn adults with nocturia, 33% with desmopressin versus 11% with placebo achieved at least 50% fewer nighttime urinations.

    Peptide
    Desmopressin
    Outcome
    IncreaseClinical response
    Study

    n = 127

    Comparator
    Placebo
    Outcome group
    Nocturia · Kidney and urinary
    Studied dose
    0.1, 0.2, or 0.4 mg · oral · 3 weeksAs given in this study (human).

    Measurements

    Responders (>=50% fewer nocturnal voids)
    20 patients
    Desmopressin
    Responders (>=50% fewer nocturnal voids)
    33%
    Desmopressin
    Responders (>=50% fewer nocturnal voids)
    7 patients
    Placebo
    Responders (>=50% fewer nocturnal voids)
    11%
    Placebo

    Source sentences

    Summary
    Twenty (33%) desmopressin-treated patients compared with seven (11%) placebo-treated patients showed a clinical response, defined as a > or =50% reduction in the number of nocturnal voids compared with baseline (p=0.0014).
    3 context sentences
    Summary · context
    Adults aged > or =18 yr with nocturia (> or =2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period.
    Summary · context
    Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo.
    Summary · context
    127 patients were randomised to either desmopressin (n=61) or placebo (n=66).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with nocturia, nocturnal voids decreased 39% with desmopressin versus 15% with placebo, an absolute difference of -0.84 (p<0.0001).

    In plain wordsIn adults with nocturia, nighttime urinations decreased 39% with desmopressin versus 15% with placebo.

    Peptide
    Desmopressin
    Outcome
    DecreaseMean nocturnal voids
    Study

    n = 127

    Comparator
    Placebo
    Outcome group
    Nocturia · Kidney and urinary
    Studied dose
    0.1, 0.2, or 0.4 mg · oral · 3 weeksAs given in this study (human).

    Measurements

    Reduction in mean nocturnal voids
    39%
    Desmopressin
    Reduction in mean nocturnal voids
    15%
    Placebo
    Absolute difference in mean nocturnal voids, desmopressin vs placebo
    −0.84 nocturnal voids
    Desmopressin vs placebo

    Source sentences

    Summary
    Compared with placebo, desmopressin resulted in a significant reduction in the mean number of nocturnal voids (39% reduction with desmopressin vs. 15% with placebo; absolute difference -0.84, p<0.0001)
    3 context sentences
    Summary · context
    Adults aged > or =18 yr with nocturia (> or =2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period.
    Summary · context
    Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo.
    Summary · context
    127 patients were randomised to either desmopressin (n=61) or placebo (n=66).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with nocturia, the first sleep period increased 108 minutes with desmopressin versus 41 minutes with placebo (p<0.0001).

    In plain wordsIn adults with nocturia, the first sleep period increased 108 minutes with desmopressin versus 41 minutes with placebo.

    Peptide
    Desmopressin
    Outcome
    IncreaseFirst sleep period duration
    Study

    n = 127

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    0.1, 0.2, or 0.4 mg · oral · 3 weeksAs given in this study (human).

    Measurements

    Prolongation of first sleep period
    108 min
    Desmopressin
    Prolongation of first sleep period
    41 min
    Placebo

    Source sentences

    Summary
    and duration of the first sleep period (prolonged by 108 min with desmopressin vs. 41 min with placebo; p<0.0001).
    3 context sentences
    Summary · context
    Adults aged > or =18 yr with nocturia (> or =2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period.
    Summary · context
    Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo.
    Summary · context
    127 patients were randomised to either desmopressin (n=61) or placebo (n=66).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with nocturia, desmopressin improved sleep quality versus placebo, significantly for one of two parameters.

    In plain wordsIn adults with nocturia, desmopressin improved sleep quality versus placebo, significantly for one of two measures.

    Peptide
    Desmopressin
    Outcome
    MixedSleep quality
    Study

    n = 127

    Comparator
    Placebo
    Outcome group
    Sleep · Sleep
    Studied dose
    0.1, 0.2, or 0.4 mg · oral · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Quality of sleep was also improved with desmopressin versus placebo (statistically significant for one of the two parameters evaluated).
    3 context sentences
    Summary · context
    Adults aged > or =18 yr with nocturia (> or =2 voids/night) received desmopressin tablets (0.1, 0.2, or 0.4 mg) during a 3-wk dose-titration period.
    Summary · context
    Eligible patients then entered a 3-wk double-blind treatment period and received either desmopressin or placebo.
    Summary · context
    127 patients were randomised to either desmopressin (n=61) or placebo (n=66).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.